Summary of Study ST000565

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR000415. The data can be accessed directly via it's Project DOI: 10.21228/M8DK6R This work is supported by NIH grant, U2C- DK119886.

See: https://www.metabolomicsworkbench.org/about/howtocite.php

Perform statistical analysis  |  Show all samples  |  Show named metabolites  |  Download named metabolite data  
Download mwTab file (text)   |  Download mwTab file(JSON)   |  Download data files (Contains raw data)
Study IDST000565
Study TitleAssociation of hemodialysis patient plasma trace metals with response to erythropoiesis stimulating agents
Study TypeMetallomics
Study SummaryEDTA-Plasma from 110 hemodialysis patients participating in an NIDDK funded study were analyzed by ICP-MS for the concentration of As, Cd, Co, Cr, Cu, Mn, Mo, Ni, Pb, Sb, Se, Sn, V, and Zn. Associations were determined between trace metals and gender, race, hemodialysis status, hemoglobin at the time of draw (Hgb), total ESA dose for the month the sample was collected (EPO), and erythropoietin resistance index determined over the 6 months of treatment leading up to sample collection (ERI)
Institute
RTI International
LaboratoryNIH Eastern Regional Comprehensive Metabolomics Resource Core at UNC Chapel Hill (ERCMRC)
Last NameSumner
First NameSusan
Address3040 E. Cornwallis Road, Research Triangle Park, NC 27709, USA
Emailsusan_sumner@unc.edu
Phone704-250-5000
Submit Date2017-02-27
Total Subjects110
Raw Data AvailableYes
Raw Data File Type(s)dat
Analysis Type DetailICP-MS
Release Date2018-08-27
Release Version1
Susan Sumner Susan Sumner
https://dx.doi.org/10.21228/M8DK6R
ftp://www.metabolomicsworkbench.org/Studies/ application/zip

Select appropriate tab below to view additional metadata details:

Subject:

Subject ID:SU000587
Subject Type:Human
Subject Species:Homo sapiens
Taxonomy ID:9606
Gender:Both
Human Trial Type:validation/discovery trial
Human Inclusion Criteria:All subjects will receive hemodialysis in-center on a 3 times per week dialysis schedule. Subjects are eligible to participate if 1) subjects that have received EPO will have received it for 6 or more months, 2) between the ages of 18 and 80 years, 3) have an adequacy of dialysis (Kt/V) that is ≥ 1.2, 4) have adequate iron stores as measured by ferritin and transferrin saturation.
Human Exclusion Criteria:None
Species Group:Human
  logo